Trending...
- House of Buneau Releases "Pretty Boy Heaven," A Cinematic Exploration of Beauty and Distance - 111
- VBO Expands Event Manager 3.0 with Real-Time Sales Visibility, New Dashboards, and Operational Tools
- Mark Dobosz Makes Donorassess.org Free To Every Nonprofit On The Planet
SAN FRANCISCO ~ In a recent announcement, CIBC Innovation Banking revealed that it has provided growth financing to InsightRX, a San Francisco-based software company. InsightRX is known for its innovative use of quantitative pharmacology and artificial intelligence (AI) to enhance therapeutic decision-making from the early stages of drug development to the point of patient care.
InsightRX's unique approach involves utilizing patient-specific data and quantitative models to tailor dosing for complex treatments such as antibiotics, chemotherapeutic agents, and immunosuppressants. By incorporating AI technology, the company also empowers data scientists in analyzing clinical trial data, aiding in trial design, understanding dose-exposure-response relationships, and refining dosing strategies for regulatory submissions.
According to Sirj Goswami, Ph.D., CEO and co-founder of InsightRX, their goal is to shift away from the traditional "one-size-fits-all" approach in drug dosing towards a more individualized treatment paradigm. This not only benefits patient care but also has a significant impact on the introduction of new drugs to the market. To achieve their strategic vision of transforming patient care, InsightRX sought out financing from CIBC and found them to be an ideal partner due to their intellectual curiosity about the intricacies of their business and thoughtful approach.
More on The Californer
John Flemming, managing director of CIBC Innovation Banking's Seattle office expressed excitement about working with InsightRX's leadership team. He believes that their use of AI technology will pave the way for advancements in drug development within biopharma clinical trials and improve healthcare providers' ability to ensure optimal drug dosing for patients. Flemming also noted that InsightRX will play a crucial role in enhancing the development of new therapies that prioritize patient safety throughout the healthcare drug development and delivery chain.
With this new financing from CIBC Innovation Banking, InsightRX is well-positioned to continue its groundbreaking work in revolutionizing drug dosing and improving patient outcomes. As they continue to lead the way in this field, InsightRX and CIBC are poised to make a significant impact on the future of healthcare.
InsightRX's unique approach involves utilizing patient-specific data and quantitative models to tailor dosing for complex treatments such as antibiotics, chemotherapeutic agents, and immunosuppressants. By incorporating AI technology, the company also empowers data scientists in analyzing clinical trial data, aiding in trial design, understanding dose-exposure-response relationships, and refining dosing strategies for regulatory submissions.
According to Sirj Goswami, Ph.D., CEO and co-founder of InsightRX, their goal is to shift away from the traditional "one-size-fits-all" approach in drug dosing towards a more individualized treatment paradigm. This not only benefits patient care but also has a significant impact on the introduction of new drugs to the market. To achieve their strategic vision of transforming patient care, InsightRX sought out financing from CIBC and found them to be an ideal partner due to their intellectual curiosity about the intricacies of their business and thoughtful approach.
More on The Californer
- Certified Trading Card Association and Collectors MD Launch Healthy Hobby Initiative
- Bookish Lane Publishing Launches Global Poetry Hacking Live Experience for National Poetry Month
- El Dorado Hills Travel Announces New Ownership and Expanded Hours
- DriveYo Launches AI Platform to Expose Hidden Car Deal Markups and Return $20 Billion to Buyers
- Eric Bellinger Debuts "Cry In Front Of You" Live Following Tamla Motown Signing
John Flemming, managing director of CIBC Innovation Banking's Seattle office expressed excitement about working with InsightRX's leadership team. He believes that their use of AI technology will pave the way for advancements in drug development within biopharma clinical trials and improve healthcare providers' ability to ensure optimal drug dosing for patients. Flemming also noted that InsightRX will play a crucial role in enhancing the development of new therapies that prioritize patient safety throughout the healthcare drug development and delivery chain.
With this new financing from CIBC Innovation Banking, InsightRX is well-positioned to continue its groundbreaking work in revolutionizing drug dosing and improving patient outcomes. As they continue to lead the way in this field, InsightRX and CIBC are poised to make a significant impact on the future of healthcare.
Filed Under: Business
0 Comments
Latest on The Californer
- Rapifai and GeneSys Partner to Accelerate ADAS Verification with AI-Driven Intelligence and ground Truth Sensor Integration
- Ventura College Tutoring Center Earns National Certification for Tutor Training Excellence
- Carrington College Partners with Career Team to Enhance Career Services Through AI-Enabled Platform
- Long Beach: City to Host TGI2S+ Career and Resource Fair
- FinIQ Edu Launches High-Impact Workshop Vertical to Close the Workplace Benefits Gap—Drives 82% Surge in 401(k) Participation Intent
- HousingWire launches Mortgage Rankings, bringing a data-driven benchmark to originator performance
- California: Governor Newsom proclaims Farmworkers Day
- J&J Exterminating Reminds Residents to prepare for Termite Swarm Season
- California: Governor Newsom's border strategy intercepts 54 million lethal fentanyl pills since 2021
- Sonnenblick-Eichner Arranges $80M Loan to Refinance 162K-SF Creative Office Campus in Los Angeles
- Rediscovering Hidden Literary Gems
- Ascend in Motion Introduces Flat Rate Pricing for 310+ Destinations from LAX
- Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
- Just 1 in 57 Crypto Owners Globally Pay Taxes on Their Holdings, New Report Finds
- IQSTEL accelerates toward profitability inflection with $317M revenue and AI-driven expansion; IQSTEL Inc. (N A S D A Q: IQST) i
- AI-Driven Breakthrough Unleashed: Bionic Intelligence Platform Goes Live to Capture Massive Biotech Opportunity: KALA BIO, Inc. (N A S D A Q: KALA)
- Surging Into Hyper-Growth Mode With Record Revenue, Raised 2026 Guidance, and Game-Changing AI Platform; Off The Hook YS (NYSE American: OTH)
- Connect Names Kiana Miyamoto as Director of Life Sciences to Accelerate Founders and Ecosystem
- Mom Creators Coalition Launches with WaterWipes® as Official Founding Sponsor
- Silicon Valley Bank Shifts: AI Trading Secures 54% Annualized Return for Retail Investors